Literature DB >> 19171801

Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.

Ana Alastruey-Izquierdo1, Maria Victoria Castelli, Isabel Cuesta, Araceli Monzon, Manuel Cuenca-Estrella, Juan Luis Rodriguez-Tudela.   

Abstract

The antifungal susceptibility profiles of 77 clinical strains of Mucorales species, identified by internal transcribed spacer sequencing, were analyzed. MICs obtained at 24 and 48 h were compared. Amphotericin B was the most active agent against all isolates, except for Cunninghamella and Apophysomyces isolates. Posaconazole also showed good activity for all species but Cunninghamella bertholletiae. Voriconazole had no activity against any of the fungi tested. Terbinafine showed good activity, except for Rhizopus oryzae, Mucor circinelloides, and Rhizomucor variabilis isolates.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19171801      PMCID： PMC2663095          DOI： 10.1128/AAC.01467-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  28 in total

1.  Inoculum standardization for antifungal susceptibility testing of filamentous fungi pathogenic for humans.

Authors:  E Petrikkou; J L Rodríguez-Tudela; M Cuenca-Estrella; A Gómez; A Molleja; E Mellado
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

2.  Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi.

Authors:  A Aberkane; M Cuenca-Estrella; A Gomez-Lopez; E Petrikkou; E Mellado; A Monzón; J L Rodriguez-Tudela
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

3.  In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole.

Authors:  A Gómez-López; M Cuenca-Estrella; A Monzón; J L Rodriguez-Tudela
Journal:  J Antimicrob Chemother       Date:  2001-12       Impact factor: 5.790

4.  Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis.

Authors:  Eric Dannaoui; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 5.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

6.  Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole.

Authors:  J Mosquera; P A Warn; J L Rodriguez-Tudela; D W Denning
Journal:  J Antimicrob Chemother       Date:  2001-10       Impact factor: 5.790

7.  Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy.

Authors:  S M Trifilio; C L Bennett; P R Yarnold; J M McKoy; J Parada; J Mehta; G Chamilos; F Palella; L Kennedy; K Mullane; M S Tallman; A Evens; M H Scheetz; W Blum; D P Kontoyiannis
Journal:  Bone Marrow Transplant       Date:  2007-02-19       Impact factor: 5.483

8.  Endocarditis and hemorrhagic stroke caused by Cunninghamella bertholletiae infection after kidney transplantation.

Authors:  Rubin Zhang; Jing W Zhang; Harold M Szerlip
Journal:  Am J Kidney Dis       Date:  2002-10       Impact factor: 8.860

9.  In vitro susceptibilities of zygomycetes to conventional and new antifungals.

Authors:  Eric Dannaoui; Joseph Meletiadis; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790
View more
  27 in total

1.  In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.

Authors:  Sharon C-A Chen; Chayanika Biswas; Robyn Bartley; Fred Widmer; Namfon Pantarat; Daniel Obando; Julianne T Djordjevic; David H Ellis; Katrina A Jolliffe; Tania C Sorrell
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

2.  Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales.

Authors:  Roxana G Vitale; G Sybren de Hoog; Patrick Schwarz; Eric Dannaoui; Shuwen Deng; Marie Machouart; Kerstin Voigt; Wendy W J van de Sande; Somayeh Dolatabadi; Jacques F Meis; Grit Walther
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

3.  Direct analysis and identification of pathogenic Lichtheimia species by matrix-assisted laser desorption ionization-time of flight analyzer-mediated mass spectrometry.

Authors:  Wieland Schrödl; Tilo Heydel; Volker U Schwartze; Kerstin Hoffmann; Anke Grosse-Herrenthey; Grit Walther; Ana Alastruey-Izquierdo; Juan Luis Rodriguez-Tudela; Philipp Olias; Ilse D Jacobsen; G Sybren de Hoog; Kerstin Voigt
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

4.  Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.

Authors:  Ana Alastruey-Izquierdo; Isabel Cuesta; Grit Walther; Manuel Cuenca-Estrella; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

5.  Adaptation to thermotolerance in Rhizopus coincides with virulence as revealed by avian and invertebrate infection models, phylogeny, physiological and metabolic flexibility.

Authors:  Kerstin Kaerger; Volker U Schwartze; Somayeh Dolatabadi; Ildikó Nyilasi; Stella A Kovács; Ulrike Binder; Tamás Papp; Sybren de Hoog; Ilse D Jacobsen; Kerstin Voigt
Journal:  Virulence       Date:  2015       Impact factor: 5.882

6.  Etest cannot be recommended for in vitro susceptibility testing of mucorales.

Authors:  Rita Caramalho; Elisabeth Maurer; Ulrike Binder; Ricardo Araújo; Somayeh Dolatabadi; Cornelia Lass-Flörl; Michaela Lackner
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

7.  Invasive Apophysomyces variabilis infection in a burn patient.

Authors:  Wilfred P dela Cruz; Tatjana P Calvano; Matthew E Griffith; Christopher E White; Seung H Kim; Deanna A Sutton; Elizabeth H Thompson; Jianmin Fu; Brian L Wickes; Josep Guarro; Duane R Hospenthal
Journal:  J Clin Microbiol       Date:  2012-05-23       Impact factor: 5.948

Review 8.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

9.  Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales.

Authors:  A Espinel-Ingroff; A Chakrabarti; A Chowdhary; S Cordoba; E Dannaoui; P Dufresne; A Fothergill; M Ghannoum; G M Gonzalez; J Guarro; S Kidd; C Lass-Flörl; J F Meis; T Pelaez; A M Tortorano; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

10.  Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.

Authors:  M Mar Rodríguez; F Javier Pastor; Enrique Calvo; Valentina Salas; Deanna A Sutton; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.